Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Suzhou CF PharmTech Closes $50 Million F Round for Respiratory Drugs

publication date: Jul 3, 2020

Suzhou CF PharmTech closed a $50 million Series F round to support its portfolio of inhaled respiratory drugs. In January, the company completed a $90 million Series E round. Founded in 2007, CF develops products delivered on four platforms: HFA (hydrofluoroalkane) metered dose inhalers, nasal sprays, nebulized and dry powder products. CF, which markets the respiratory drugs in China and global markets, has its headquarters and manufacturing facilities in Suzhou and an R&D Center in WuXi. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital